Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SHE:000766)
China · Delayed Price · Currency is CNY 25.13
+0.04 (0.16%)
Feb 3, 2026, 11:25 AM CST
SHE:000766 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,246 | 1,322 | 1,470 | 1,470 | 1,514 | 1,111 |
Other Revenue | 0.5 | 0.5 | 3.57 | 0.58 | 1.32 | 0.72 |
| 1,246 | 1,323 | 1,473 | 1,471 | 1,515 | 1,112 | |
Revenue Growth (YoY) | -10.84% | -10.23% | 0.18% | -2.95% | 36.31% | -43.77% |
Cost of Revenue | 335.34 | 329.03 | 381.17 | 352.93 | 350.18 | 229.94 |
Gross Profit | 910.88 | 993.53 | 1,092 | 1,118 | 1,165 | 881.86 |
Selling, General & Admin | 694.76 | 789.26 | 905 | 923.47 | 986.24 | 1,042 |
Research & Development | 49.84 | 50.34 | 45.82 | 64.91 | 63.52 | 50.33 |
Other Operating Expenses | 13.52 | 9.88 | 10.62 | 11.57 | 5.4 | 3.96 |
Operating Expenses | 758.65 | 853.14 | 970.43 | 996.86 | 1,052 | 1,228 |
Operating Income | 152.23 | 140.39 | 121.75 | 120.96 | 113.33 | -346.24 |
Interest Expense | -84.06 | -84.98 | -83.15 | -88.79 | -97.19 | -125.27 |
Interest & Investment Income | 2.07 | 5.28 | 4.02 | 11.5 | 26.36 | 23.31 |
Other Non Operating Income (Expenses) | -5.24 | -2.66 | 1.23 | -3.64 | 3.47 | -0.37 |
EBT Excluding Unusual Items | 65 | 58.03 | 43.85 | 40.02 | 45.98 | -448.58 |
Gain (Loss) on Sale of Investments | -0 | 0.03 | -2.61 | -0.05 | -0.01 | - |
Gain (Loss) on Sale of Assets | -0.03 | -0.17 | -0.21 | -0.02 | 0.83 | 57.58 |
Asset Writedown | 2.15 | -0.12 | 0.22 | -0.11 | -1.49 | -0.43 |
Other Unusual Items | 8.76 | 9.32 | 13.61 | 10.33 | 14.32 | 35.6 |
Pretax Income | 75.88 | 67.09 | 54.86 | 50.17 | 59.62 | -355.83 |
Income Tax Expense | 18.77 | 11.11 | 11.63 | 20.99 | 25.64 | 4.83 |
Earnings From Continuing Operations | 57.11 | 55.98 | 43.23 | 29.19 | 33.99 | -360.66 |
Minority Interest in Earnings | 0.37 | 0.46 | 0.71 | 0.96 | 1.29 | 1.16 |
Net Income | 57.48 | 56.44 | 43.93 | 30.15 | 35.27 | -359.5 |
Net Income to Common | 57.48 | 56.44 | 43.93 | 30.15 | 35.27 | -359.5 |
Net Income Growth | 9.88% | 28.46% | 45.71% | -14.52% | - | - |
Shares Outstanding (Basic) | 943 | 941 | 879 | 1,005 | 882 | 972 |
Shares Outstanding (Diluted) | 943 | 941 | 879 | 1,005 | 882 | 972 |
Shares Change (YoY) | 7.41% | 7.05% | -12.57% | 13.97% | -9.24% | 0.40% |
EPS (Basic) | 0.06 | 0.06 | 0.05 | 0.03 | 0.04 | -0.37 |
EPS (Diluted) | 0.06 | 0.06 | 0.05 | 0.03 | 0.04 | -0.37 |
EPS Growth | 2.30% | 20.00% | 66.67% | -25.00% | - | - |
Free Cash Flow | 66.56 | 113.58 | 86.11 | 174.42 | 112.85 | 61.55 |
Free Cash Flow Per Share | 0.07 | 0.12 | 0.10 | 0.17 | 0.13 | 0.06 |
Gross Margin | 73.09% | 75.12% | 74.13% | 76.00% | 76.89% | 79.32% |
Operating Margin | 12.21% | 10.62% | 8.26% | 8.22% | 7.48% | -31.14% |
Profit Margin | 4.61% | 4.27% | 2.98% | 2.05% | 2.33% | -32.34% |
Free Cash Flow Margin | 5.34% | 8.59% | 5.85% | 11.86% | 7.45% | 5.54% |
EBITDA | 208.92 | 204.82 | 196.49 | 192.58 | 182.72 | -278.53 |
EBITDA Margin | 16.76% | 15.49% | 13.34% | 13.09% | 12.06% | -25.05% |
D&A For EBITDA | 56.69 | 64.42 | 74.74 | 71.62 | 69.39 | 67.71 |
EBIT | 152.23 | 140.39 | 121.75 | 120.96 | 113.33 | -346.24 |
EBIT Margin | 12.21% | 10.62% | 8.26% | 8.22% | 7.48% | -31.14% |
Effective Tax Rate | 24.74% | 16.56% | 21.20% | 41.83% | 42.99% | - |
Revenue as Reported | 1,246 | 1,323 | 1,473 | 1,471 | 1,515 | 1,112 |
Advertising Expenses | - | 249.73 | 352.83 | 298.68 | 375.06 | 299.1 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.